FDA grants Precigen platform technology designation for AdenoVerse

Go back to FDA grants Precigen platform technology designation for AdenoVerse

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

September 21, 2026 7:00 AM EDT

Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform

GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a... More